First Tracks Biotherapeutics Price Target Raised to $72.08 by Analysts
Wall Street analysts covering First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) have nudged their average 12-month price target higher to $72.08, up from the previous consensus of $71.25. The revised consensus target reflects price projections that range between a low of $57 and a high of $100 per share across 12 covering analysts.
The updated average target represents an estimated potential gain of around 126% compared to the stock's closing price on Oct. 9. Market sentiment toward the biotechnology firm remains uniformly positive, with all 12 analysts maintaining a Buy recommendation and zero Hold or Sell ratings recorded. Shares of the company traded up 6.91% at $34.05 today.
Investors will be watching whether upcoming developments and pipeline updates from the company keep analysts aligned around their bullish target range.
Key points
- Analyst consensus price target for First Tracks Biotherapeutics rose from $71.25 to $72.08.
- Individual price targets among 12 analysts range from $57 to $100 per share.
- The updated price target implies approximately 126% upside from the October 9 closing price.
- All 12 covering analysts maintain a Buy rating on the stock with zero Hold or Sell ratings.
- Shares of NASDAQ:TRAX gained 6.91% today to reach $34.05.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the updated price target for First Tracks Biotherapeutics?
The average 12-month price target for First Tracks Biotherapeutics is $72.08, up from $71.25. Individual analyst forecasts range from $57 to $100 per share.
What is the analyst rating for First Tracks Biotherapeutics stock?
All 12 analysts covering the stock give it a Buy rating, resulting in a unanimous Buy consensus rating with no Hold or Sell recommendations.
How much upside does the price target imply for TRAX stock?
Based on the October 9 closing price, the $72.08 average price target implies an upside potential of approximately 126%.